How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
ConclusionsAn overlapping effect of hyperinflammation, hypoxic organ injury and drug-related toxicity warrants a long-term follow-up for COVID-19 survivors. In addition, residual IL-6 receptors blockage may mask new infections. A standardized approach to follow-up for COVID-19 survivors is urgently needed. Current and future research should also investigate the impact of experimental therapies on lung tissue healing and regeneration, as well as long-term treatment toxicities.
Source: European Journal of Medical Research - Category: Research Source Type: research
More News: Actemra | Azithromycin | COVID-19 | Infectious Diseases | Research | Toxicology | Zithromax